Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
ETONDEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States.
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
ETONDEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
ETONDEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2025.
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
ETONEton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35
ETONEton Pharmaceuticals Receives U.S. FDA Approval For KHINDIVI Oral Solution
ETONB. Riley Securities Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $26
ETONA Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts
ETONCraig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $28
ETONEton Pharmaceuticals Q1 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $17.28M Beat $15.13M Estimate
ETONA Look Ahead: Eton Pharmaceuticals's Earnings Forecast
ETONEton Pharma Submits NDA To FDA For Proprietary Desmopressin Oral Solution ET-600; Anticipates Q1 2026 Launch After 10-month Review
ETONEton Pharmaceuticals Out-Incenses Commercial Rights To Increlex In Territories Outside Of The US To Esteve Pharmaceuticals
ETONCraig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $26
ETONB. Riley Securities Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $24
ETON5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
ETONHC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $33 Price Target
ETONEton Pharmaceuticals Q4 2024 GAAP EPS $(0.02) Vs. $(0.09) YoY, Sales $11.65M Beat $10.53M Estimate
ETONEton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
ETONEton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026.
Eton Pharmaceuticals Announces Results From Bioequivalence Study Of ET-600 For Treatment Of Central Diabetes Insipidus; To Submit New Drug Application In April 2025
ETONEton Pharmaceuticals Releases FDA-Approved Galzin Capsules for Long-Term Wilson Disease Management
ETONB. Riley Securities Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $21
ETONEton Pharmaceuticals Announces Acquisition Of FDA-Approved Rare Disease Product, Betaine Anhydrous For Oral Solution
ETON